Načítá se...
Developing pharmacological therapies for Alzheimer disease
Alzheimer disease (AD), while chronic and progressive with an average progression of 7–10 years, is both multifactorial and heterogeneous. Thus, AD offers a large window of opportunity and a large number of therapeutic targets to inhibit it. The selection of a therapeutic target, however, is one of...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2007
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3139452/ https://ncbi.nlm.nih.gov/pubmed/17604997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00018-007-7221-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|